RGB-14-P + Prolia®
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Postmenopausal Osteoporosis
Conditions
Postmenopausal Osteoporosis
Trial Timeline
Sep 21, 2021 → Nov 15, 2023
NCT ID
NCT05087030About RGB-14-P + Prolia®
RGB-14-P + Prolia® is a phase 3 stage product being developed by Richter Gedeon for Postmenopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05087030. Target conditions include Postmenopausal Osteoporosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05087030 | Phase 3 | Completed |
Competing Products
20 competing products in Postmenopausal Osteoporosis